|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | ONE KAISER PLAZA, ORDWAY BLDG. |
Address2 | 27th FLOOR |
City | OAKLAND |
State | CA |
Zip Code | 94612 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 21027-12
|
||||||||
|
6. House ID# 300780000
|
TYPE OF REPORT | 8. Year | 2019 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Anthony Barrueta |
Date | 1/23/2020 3:09:20 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
HR 2328, PCORI Reauthorization
HR 2328, the No Surprises Act
S. 1895, the Lower Health Care Costs Act
HR 987 and S. 455, regarding outreach and education activities under the ACA
HR 3439, regarding the reauthorization of PCORI
House Resolution 271, regarding the Justice Departments position in Texas v. United States
HR 2062 & S. 1012, regarding 42 CFR Part 2 and confidentiality of certain health information
HR 1884, with provisions to stabilize and strengthen the ACA and the nongroup insurance market.
S. 470, regarding a Medicare buy-in option for individuals aged 50-64
S. 489 and HR 1277, regarding a Medicaid buy-in option
S. 1129, to establish a single payer system based on Medicare for All.
HR 1384, to establish a single payer health care system
HR 1425, regarding reinsurance funding under the ACA
HR 986 and S. 466, regarding Section 1332 state waiver guidance.
HR 1010, regarding Short Term Limited Duration Insurance policies
HR 1143, regarding Short Term Limited Duration Insurance policies
HR 861, regarding surprise billing
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Laird |
Burnett |
|
|
|
Fish |
Brown |
|
|
|
Mary Prudence |
Fitzpatrick |
|
|
|
David |
Bennett |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
S. 2543, Prescription Drug Pricing Reduction Act
HR 2296, regarding prescription drug pricing
HR 3, regarding prescription drug pricing (Pelosi)
HR 4455, regarding Biologics in Medicare Part D
S. 6748, regarding the Cadillac tax
HR 4378, Continuing Appropriations and Health Extenders Act
S. 2543, Prescription Drug Pricing Reduction Act
HR 1781, regarding access to data for MedPAC and MACPAC
HR 2113, regarding drug price transparency
HR 2374, regarding generic drugs and citizens petitions
HR 2375, regarding pay for delay agreements and generic drugs
HR 2376, regarding the Federal Trade Commissions role in assuring competition in the pharmaceutical supply chain
HR 2064, regarding reporting of prescription drug samples given to physicians by manufacturers
HR 478 and S. 61, regarding drug reimportation
HR 965 and S 340, regarding abuse of Risk Evaluation and Mitigation Strategies (REMS) (CREATES Act)
HR 1499, regarding pay for delay in pharmaceutical markets
HR 1503, regarding the FDA Orange Book
HR 1520, regarding the FDA Purple Book
HR 938, regarding generic drug approvals
HR 2113, regarding drug pricing transparency
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Laird |
Burnett |
|
|
|
Fish |
Brown |
|
|
|
Mary Prudence |
Fitzpatrick |
|
|
|
David |
Bennett |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
HR 4378, Continuing Appropriations and Health Extenders Act
HR 1839, the Medicaid Services Investment and Accountability Act
HR 3253, The Empowering Beneficiaries, Ensuring Access and Strengthening Accountability Act (regarding Medicaid)
HR 2131 and S. 1114, regarding the Medicare Advantage benchmark cap
HR 3107, regarding the use of preauthorization in the Medicare Advantage program
HR 3417 the Beneficiary Education Tools, Telehealth and Extenders Reauthorization Act (regarding Medicare)
Legislation and regulation regarding the Medicare Advantage program
HR 1839, regarding multiple Medicaid program changes, including the Medicaid Drug Rebate program.
HR 2131 and S. 1114, to remove the Medicare benchmark cap.
HR 1046 and S. 377, regarding Medicare Part D and requirements for HHS to negotiate drug prices
HR 1781 Regarding MedPAC and MACPAC access to drug pricing and rebate data.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Laird |
Burnett |
|
|
|
Fish |
Brown |
|
|
|
Mary Prudence |
Fitzpatrick |
|
|
|
David |
Bennett |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
S. 6748, regarding the Cadillac tax
HR 2447, to repeal the health insurance tax contained in the ACA
HR 748, Regarding the Cadillac tax on high cost employer provided health coverage.
S. 80, to repeal the ACA health insurance tax.
S. 172, to suspend for two years the ACA health insurance tax.
HR 1398, to suspend the ACA health insurance tax for two years.
S. 73, regarding the tax deduction for direct-to-consumer advertising
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Laird |
Burnett |
|
|
|
Fish |
Brown |
|
|
|
Mary Prudence |
Fitzpatrick |
|
|
|
David |
Bennett |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code DEF
16. Specific lobbying issues
Legislation and regulation regarding the TRICARE program
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Laird |
Burnett |
|
|
|
Fish |
Brown |
|
|
|
Mary Prudence |
Fitzpatrick |
|
|
|
David |
Bennett |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |